Ropes & Gray advised ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a research collaboration with Biosion USA, a global research & development biotechnology company, to create novel antibody-drug conjugates. The collaboration was announced on December 13. Financial terms were not disclosed.
In the joint research effort, Biosion will leverage its high-throughput endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their linker-payload technology to create novel ADCs.
The Ropes & Gray team was led by life sciences licensing partner Amanda Austin and IP transactions associate Sarah Smith.
